MX2019007749A - Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5. - Google Patents

Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.

Info

Publication number
MX2019007749A
MX2019007749A MX2019007749A MX2019007749A MX2019007749A MX 2019007749 A MX2019007749 A MX 2019007749A MX 2019007749 A MX2019007749 A MX 2019007749A MX 2019007749 A MX2019007749 A MX 2019007749A MX 2019007749 A MX2019007749 A MX 2019007749A
Authority
MX
Mexico
Prior art keywords
related disease
prevention
treating
preventing
treatment
Prior art date
Application number
MX2019007749A
Other languages
English (en)
Spanish (es)
Inventor
Haraya Kenta
Yoneyama Koichiro
Sampei Zenjiro
Shibahara Norihito
Shinomiya Kenji
Tsuboi Yoshinori
Bogman Katrijn
FUKUZAWA Taku
Eric Charoin Jean
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SG10201700775YA external-priority patent/SG10201700775YA/en
Priority claimed from SG10201705954VA external-priority patent/SG10201705954VA/en
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2019007749A publication Critical patent/MX2019007749A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
MX2019007749A 2017-01-31 2018-01-31 Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5. MX2019007749A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201700775YA SG10201700775YA (en) 2017-01-31 2017-01-31 A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease
SG10201705954VA SG10201705954VA (en) 2017-07-20 2017-07-20 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
PCT/JP2018/003193 WO2018143266A1 (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease

Publications (1)

Publication Number Publication Date
MX2019007749A true MX2019007749A (es) 2019-09-09

Family

ID=61617058

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007749A MX2019007749A (es) 2017-01-31 2018-01-31 Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.
MX2022012931A MX2022012931A (es) 2017-01-31 2019-06-26 Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022012931A MX2022012931A (es) 2017-01-31 2019-06-26 Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.

Country Status (19)

Country Link
US (3) US20190367599A1 (https=)
EP (2) EP4223774A3 (https=)
JP (4) JP6383122B2 (https=)
KR (4) KR102365871B1 (https=)
CN (1) CN110167961A (https=)
AU (2) AU2018215039B2 (https=)
BR (1) BR112019015426A2 (https=)
CA (1) CA3051389A1 (https=)
CR (2) CR20220563A (https=)
ES (1) ES2947735T3 (https=)
IL (2) IL268327B2 (https=)
MX (2) MX2019007749A (https=)
MY (1) MY201148A (https=)
PH (1) PH12019501706A1 (https=)
PL (1) PL3577135T3 (https=)
SG (2) SG10201908697XA (https=)
TW (3) TW202412841A (https=)
UA (1) UA129282C2 (https=)
WO (1) WO2018143266A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
CN118512588A (zh) * 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
CA3274059A1 (en) 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
EP3802603A1 (en) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
EP3873602B1 (en) * 2018-10-30 2023-12-06 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
KR20240033090A (ko) * 2019-07-31 2024-03-12 에프. 호프만-라 로슈 아게 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
CR20220040A (es) 2019-07-31 2022-03-02 Hoffmann La Roche Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab
CA3153195A1 (en) * 2019-10-25 2021-04-29 John Davis Dosing regimens for treating or preventing c5-associated diseases
CA3196434A1 (en) * 2020-10-23 2022-04-28 Krista K. JOHNSON Methods of treating patients having complement disorders using anti-c5 antibodies
JP2024060738A (ja) 2022-10-20 2024-05-07 セイコーエプソン株式会社 気体分離膜

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2896631A1 (en) 2000-10-10 2015-07-22 Genentech, Inc. Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
ES2283594T5 (es) 2001-08-17 2016-03-15 Genentech, Inc. Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
JP5932670B2 (ja) 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
IL288931B2 (en) * 2013-03-14 2025-05-01 Alnylam Pharmaceuticals Inc Compositions comprising a complementary portion of C5 IRNA and methods of using them
EP2978451B1 (en) * 2013-03-29 2019-11-27 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
BR112017011235A2 (pt) * 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
EP3313437A1 (en) * 2015-06-26 2018-05-02 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
EP3402816A1 (en) 2016-01-11 2018-11-21 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
WO2017132259A1 (en) 2016-01-25 2017-08-03 Shire Human Genetic Therapies, Inc. Anti-c5 antibodies with enhanced ph switch

Also Published As

Publication number Publication date
US20230250162A1 (en) 2023-08-10
PL3577135T3 (pl) 2023-12-04
UA129282C2 (uk) 2025-03-12
CN110167961A (zh) 2019-08-23
TWI828672B (zh) 2024-01-11
JP7581292B2 (ja) 2024-11-12
NZ756629A (en) 2025-09-26
KR20190104982A (ko) 2019-09-11
IL307593A (en) 2023-12-01
EP3577135A1 (en) 2019-12-11
AU2024216280A1 (en) 2024-09-12
US20200407432A1 (en) 2020-12-31
SG11201801401UA (en) 2018-09-27
EP4223774A2 (en) 2023-08-09
WO2018143266A1 (en) 2018-08-09
MY201148A (en) 2024-02-07
BR112019015426A2 (pt) 2020-05-26
JP6383122B2 (ja) 2018-08-29
JP2018123125A (ja) 2018-08-09
AU2018215039A1 (en) 2019-09-19
KR20230043247A (ko) 2023-03-30
CA3051389A1 (en) 2018-08-09
JP2018141025A (ja) 2018-09-13
IL268327A (en) 2019-09-26
PH12019501706A1 (en) 2020-03-16
MX2022012931A (es) 2022-11-08
TW202412841A (zh) 2024-04-01
TW201922286A (zh) 2019-06-16
JP2022168209A (ja) 2022-11-04
IL268327B2 (en) 2025-09-01
SG10201908697XA (en) 2019-10-30
KR20180099625A (ko) 2018-09-05
KR102365871B1 (ko) 2022-02-21
RU2019126664A (ru) 2021-03-02
CR20190403A (es) 2019-10-10
KR101949891B1 (ko) 2019-02-19
JP2025016617A (ja) 2025-02-04
AU2018215039B2 (en) 2024-06-13
EP4223774A3 (en) 2023-09-27
KR20220027265A (ko) 2022-03-07
US20190367599A1 (en) 2019-12-05
RU2019126664A3 (https=) 2021-05-25
JP7141865B2 (ja) 2022-09-26
TWI658834B (zh) 2019-05-11
ES2947735T3 (es) 2023-08-17
CR20220563A (es) 2022-12-07
EP3577135B1 (en) 2023-04-19
TW201831201A (zh) 2018-09-01
IL268327B1 (en) 2025-05-01
KR102514175B1 (ko) 2023-03-29

Similar Documents

Publication Publication Date Title
MX2022012931A (es) Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.
MX2021000516A (es) Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.
CL2018002708A1 (es) Métodos para la inhibición de la angiogénesis en un sujeto que lo necesita
CO2018003542A2 (es) Anticuerpo anti-garp
BR112022008294A2 (pt) Composições de profármaco e métodos de tratamento
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
MX2019015124A (es) Composicion que comprende manosa oligosacarido y proceso para realizarla y uso de esta.
MX392470B (es) Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
UY37449A (es) Anticuerpos anti-chikv y usos de éstos
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
BR112017013982A2 (pt) fármaco de combinação
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
CO2021007006A2 (es) Moduladores de la expresión de irf5
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
UY36801A (es) PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCION DE CONDICIONES INMUNES RELACIONADAS CON INFECCIONES UTILIZANDO UNA COMPOSICION QUE COMPRENDE IgM
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
EA202090827A1 (ru) Пероральные композиции для лечения гастроэзофагеального рефлюкса
CO2020003134A2 (es) Moduladores de la expresión de enac
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
EA202090485A1 (ru) Способы лечения рака путем ингибирования setd2
MX391162B (es) Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5